. Divisão de Pneumologia, Instituto do Coração - InCor - Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP) Brasil.
. Faculdade de Ciências Médicas, Santa Casa de Misericórdia de São Paulo, São Paulo (SP) Brasil.
J Bras Pneumol. 2021 Dec 15;47(6):e20210273. doi: 10.36416/1806-3756/e20210273. eCollection 2021.
Advances in the understanding that severe asthma is a complex and heterogeneous disease and in the knowledge of the pathophysiology of asthma, with the identification of different phenotypes and endotypes, have allowed new approaches for the diagnosis and characterization of the disease and have resulted in relevant changes in pharmacological management. In this context, the definition of severe asthma has been established, being differentiated from difficult-to-control asthma. These recommendations address this topic and review advances in phenotyping, use of biomarkers, and new treatments for severe asthma. Emphasis is given to topics regarding personalized management of the patient and selection of biologicals, as well as the importance of evaluating the response to treatment. These recommendations apply to adults and children with severe asthma and are targeted at physicians involved in asthma treatment. A panel of 17 Brazilian pulmonologists was invited to review recent evidence on the diagnosis and management of severe asthma, adapting it to the Brazilian reality. Each of the experts was responsible for reviewing a topic or question relevant to the topic. In a second phase, four experts discussed and structured the texts produced, and, in the last phase, all experts reviewed and approved the present manuscript and its recommendations.
在深入理解严重哮喘是一种复杂和异质性疾病以及哮喘病理生理学的基础上,通过识别不同的表型和内型,为疾病的诊断和特征描述提供了新的方法,并导致药物治疗方面的重要变化。在此背景下,严重哮喘的定义已经确立,与难治性哮喘相区别。本建议针对这一主题,综述了严重哮喘的表型、生物标志物的应用以及新的治疗方法。重点关注患者个体化管理和生物制剂选择的主题,以及评估治疗反应的重要性。这些建议适用于成人和儿童严重哮喘患者,并针对参与哮喘治疗的医生。邀请了 17 位巴西肺病学家小组审查了严重哮喘的诊断和管理方面的最新证据,使其适应巴西的实际情况。每位专家负责审查与主题相关的一个或多个主题或问题。在第二阶段,四位专家讨论和构建了生成的文本,在最后阶段,所有专家审查并批准了本手稿及其建议。